推荐产品
描述
AldrichCPR
形狀
solid
SMILES 字串
CS(=O)(CCNCC1=CC=C(C2=CC=C3N=CN=C(C3=C2)NC4=CC=C(C(Cl)=C4)OCC5=CC=CC(F)=C5)O1)=O
InChI
1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)
InChI 密鑰
BCFGMOOMADDAQU-UHFFFAOYSA-N
基因資訊
human ... EGFR(1956) , ERBB2(2064)
正在寻找类似产品? 访问 产品对比指南
一般說明
拉帕替尼是一种以表皮生长因子受体ErbB1和ErbB-2为靶点的酪氨酸激酶抑制剂。据报道它与曲妥珠单抗联合使用时在乳腺癌中具有互补作用和抗肿瘤增效活性。
其他說明
请注意，Sigma-Aldrich将此产品作为一系列独特化学品的一部分提供给早期发现的研究人员。Sigma-Aldrich不会收集该产品的分析数据。买方承担确认产品标识和纯度的责任。所有销售均为最终销售。
尽管SIGMA-ALDRICH的标准条款和条件以及SIGMA-ALDRICH和买方之间的协议中包含所有合同条款，但无论是在法律、交易过程、执行过程中的行为、以及贸易或其他方面的使用等过程中，SIGMA-ALDRICH按“原样”销售此产品并且并对此产品不作任何陈述或担保，包括：(A)适销性担保；(B)特定用途适用性担保；或(C)未侵犯第三方知识产权担保。
尽管SIGMA-ALDRICH的标准条款和条件以及SIGMA-ALDRICH和买方之间的协议中包含所有合同条款，但无论是在法律、交易过程、执行过程中的行为、以及贸易或其他方面的使用等过程中，SIGMA-ALDRICH按“原样”销售此产品并且并对此产品不作任何陈述或担保，包括：(A)适销性担保；(B)特定用途适用性担保；或(C)未侵犯第三方知识产权担保。
訊號詞
Warning
危險聲明
危險分類
Aquatic Chronic 4 - Eye Irrit. 2 - Lact.
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
其他客户在看
Melinda Halasz et al.
Science signaling, 9(455), ra114-ra114 (2016-11-24)
Signal transduction networks are often rewired in cancer cells. Identifying these alterations will enable more effective cancer treatment. We developed a computational framework that can identify, reconstruct, and mechanistically model these rewired networks from noisy and incomplete perturbation response data
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Baselga J, et al.
The Lancet, 379(9816), 633-640 (2012)
Sydney M Shaffer et al.
Nature, 546(7658), 431-435 (2017-06-14)
Therapies that target signalling molecules that are mutated in cancers can often have substantial short-term effects, but the emergence of resistant cancer cells is a major barrier to full cures. Resistance can result from secondary mutations, but in other cases
Tushar Piyush et al.
Cell death and differentiation, 24(11), 1937-1947 (2017-07-22)
Epidermal growth factor receptor (EGFR) is an important regulator of epithelial cell growth and survival in normal and cancerous tissues and is a principal therapeutic target for cancer treatment. EGFR is associated in epithelial cells with the heavily glycosylated transmembrane
Denis M Collins et al.
Cellular immunology, 319, 35-42 (2017-07-25)
Trastuzumab is an anti-HER2 monoclonal antibody (mAb) therapy capable of antibody-dependent cell-mediated cytotoxicity (ADCC) and used in the treatment of HER2+ breast cancer. Through interactions with FcƴR+ immune cell subsets, trastuzumab functions as a passive immunotherapy. The EGFR/HER2-targeting tyrosine kinase
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门